Product mentioned on podcasts
Blue808
by Blueprint Medicines
Mentioned on 1 episode by 1 guest across our covered podcasts.
SignalCast may earn commission on purchases via these links. As an Amazon Associate, SignalCast earns from qualifying purchases.
Who mentioned it
- Kate HavilandAuthor
“Blueprint's $9.1 billion Sanofi acquisition originated as a partnership discussion around pipeline asset Blue808, a wild-type KIT inhibitor targeting broad type-2 inflammation diseases like asthma and chronic urticaria.”
Mentioned on: The Long Run with Luke Timmerman